Answers are grounded in this paper and cite their sources.
Bloodstream infection (BSI) is a major cause of morbidity and mortality in neonates and children. This narrative review examines antimicrobial resistance (AMR) in pediatric BSI, with an emphasis on neonatal and hospital-onset infection. The literature was updated through 1 September 2026, using PubMed-indexed records and institutional guidance. Evidence was interpreted by age, infection setting, study design, and microbiological denominator. European and community-acquired cohorts show that pathogen distribution and resistance vary with age, care setting, and previous healthcare exposure. Extended-spectrum beta-lactamase-producing and carbapenem-resistant Enterobacterales limit empirical treatment options in several neonatal units. Observational data link discordant empirical therapy with higher mortality, although severity and healthcare exposure may confound this association. Differences in sampling, susceptibility testing, and surveillance coverage prevent a reliable comparison of global pediatric BSI trends. Candida auris is considered separately because colonization, invasive infection, and healthcare transmission require different responses. Priorities include obtaining adequate blood cultures, selecting empirical therapy based on age- and unit-specific susceptibility data, and promptly reviewing treatment when results become available. Harmonized surveillance and pediatric treatment studies are needed to determine which approaches improve clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Elkossi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: